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events were collected. Erlotinib-related rash, interventions 
for the symptoms, and outcomes of the interventions were 
analyzed.
Results A total of 9909 patients were evaluated. Rash 
occurred in 67.4 % of patients; grade 1, 2, and 3 rash were 
observed in 26.8 %, 32.4 %, and 7.2 % of patients, respec-
tively. The most common management strategy was topi-
cal steroids in 75.0 % of patients with rash. Regardless of 
rash grade, earlier initiation of steroids resulted in quicker 
recovery. In those for whom topical steroids were initiated 
more than 21 days after rash onset, median recovery time 
was more than 100 days regardless of rash grade, com-
pared with those treated before rash onset, whose median 
time to recovery was 35–51 days, depending on rash grade. 
Median time to recovery of rash in the group initiated on 
medium-rank steroids then changed to strong-rank steroids 
was 47, 98, and 103 days for those with grade 1, 2, and 
3 rash, respectively, compared with 39, 53, and 73 days 
median recovery for grade 1, 2, and 3 rash, respectively, in 
patients initiated on strong-rank steroids.
Conclusion Earlier initiation of topical steroids for the 
management of rash with strong or higher-rank steroids 
could achieve faster improvement.
Keywords Non-small-cell lung cancer · Erlotinib · 
Japanese · Rash management · Steroids
Introduction
Erlotinib is an orally administered epidermal growth fac-
tor receptor (EGFR) tyrosine-kinase inhibitor (TKI). The 
phase III BR.21 study showed that erlotinib treatment of 
non-small-cell lung cancer (NSCLC) in the second- or 
third-line setting achieved significant overall survival (OS), 
Abstract 
Background Skin toxicities, such as rash, are the most 
common adverse reactions associated with erlotinib. Ster-
oids are a key treatment option for rash management; 
however, optimal timing of administration and selection 
of steroid strength have not been fully established. In this 
surveillance study of Japanese non-small-cell lung cancer 
(NSCLC) patients treated with erlotinib, rash manage-
ment using topical steroids was analyzed in routine clinical 
practice.
Methods From December 2007 to October 2009, all 
recurrent/advanced NSCLC patients in Japan treated with 
erlotinib were enrolled into this study (POst-Launch All-
patient Registration Surveillance in TARceva). The obser-
vation period was 12 months, and data for all adverse 
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progression-free survival (PFS), and response rate benefit 
compared with best supportive care [1]. In addition, the 
OPTIMAL and EURTAC studies have reported signifi-
cant PFS benefits with erlotinib as first-line treatment for 
patients with EGFR mutation-positive NSCLC compared 
with chemotherapy in Asian and European populations, 
respectively [2, 3].
Skin toxicities (especially acneiform rash) are the most 
common adverse reactions associated with erlotinib treat-
ment [4, 5]. Across NSCLC phase III studies, the incidence 
of rash is 62–76 % [6]. This finding is not unexpected as 
EGFR is expressed in undifferentiated and proliferating 
keratinocytes of the skin, meaning that EGFR TKIs often 
result in skin toxicity [7]. The most common erlotinib-
related skin toxicities are acneiform rash, xeroderma, paro-
nychia, and pruritus [8–10].
The incidence of skin rash in Japanese patients treated 
with erlotinib has been high, with up to 98.1 % of patients 
experiencing rash [8]. In phase II studies, 72.2 % of Japa-
nese patients experienced xeroderma, which is charac-
terized by dry, rough skin causing fissures and a scaling 
effect [9]. Pruritus, or skin itching, is common with the 
development of rash or xeroderma. Paronychia is a painful 
erythema around several fingernails or toenails, which can 
result in swelling, granulation, and bleeding.
Although most cases of skin toxicities are mild and tran-
sient, they can have a considerable impact on patients’ qual-
ity of life and can therefore reduce compliance with erlo-
tinib therapy. A number of studies have reported evidence 
suggesting a correlation between the incidence and sever-
ity of rash with improved clinical outcomes, such as longer 
OS among erlotinib-treated patients [11–13]. In the BR.21 
study, all grades of rash were associated with longer OS 
compared with patients who did not develop rash [grade 1 
rash vs. no rash: hazard ratio (HR) 0.41; P < 0.001; grade 
≥2 rash vs. no rash: HR 0.29; P < 0.001] [13]. An associa-
tion between rash and prolonged OS has also been reported 
in Japanese patients (OS 8.8 months for patients with no rash 
compared with 16.6 months for patients with grade 2/3 rash) 
[14]. Considering the correlation between rash and survival 
outcomes, adequate rash management (prophylactic cleans-
ing regimens, reducing the dose or interruption of erlotinib 
treatment, or use of concomitant treatment for rash) is of the 
utmost importance to ensure the continuation of erlotinib 
treatment and therefore the maximum benefit for patients.
Kiyohara et al. developed an algorithm for rash manage-
ment (i.e., treatment course for rash symptoms) consisting 
of the use of strong or higher-class steroids to ‘manage’ 
rash, allowing patients to continue erlotinib use [15]. The 
use of steroids is an option for rash management depend-
ing on the grade of rash. In Japan, a five-class ranking sys-
tem for steroids is used ranging from the strongest to very 
strong, strong, medium, and weak. It is generally advised 
that only strong or higher-potency steroids are used to 
treat grade ≥2 erlotinib-related rash [15]. Topical steroids 
(strong or higher rank) for grade ≥2 toxicities are recom-
mended to treat both xeroderma and pruritus. Strong or 
higher-rank steroids are recommended for the treatment of 
paronychia.
This analysis was part of the POst-Launch All-patient 
Registration Surveillance in TARceva (POLARSTAR) 
study [10]. POLARSTAR is a large-scale surveillance 
study undertaken as a post-approval commitment to moni-
tor the efficacy and safety of erlotinib in Japan. This current 
analysis evaluates the use of topical steroids as a treatment 
for rash. The frequency of skin toxicity-related adverse 




In this phase IV observational study, all patients with unre-
sectable, recurrent, or advanced NSCLC who were treated 
with erlotinib were enrolled. The study was approved by 
the relevant ethics committees.
Treatment schedule
Patients receiving erlotinib daily were monitored until ter-
mination of erlotinib therapy or completion of 12 months 
of treatment. Erlotinib treatment delay, dose reduction, and 
discontinuation were permitted in actual clinical practice to 
manage rash.
Assessments
Demographic and baseline data were collected for each 
patient, including age, gender, body mass index, tumor his-
tology, Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS), smoking history, and medical history 
(including hepatic dysfunction, renal dysfunction, cardio-
vascular disease, and lung disorders). Safety data were col-
lected at 1, 6, and 12 months after the start of erlotinib ther-
apy. All AE reports were collected, and AEs were graded 
using the National Cancer Institute Common Terminology 
Criteria for AEs version 3.0 and coded using the Medical 
Dictionary for Regulatory Activities version 14.1 thesaurus 
terms.
Outcome measures
Frequency of erlotinib-related skin toxicities (acneiform 
rash, xeroderma, pruritus, and paronychia), interventions 
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for the symptoms, and the outcomes of these interven-
tions were assessed by time to treatment initiation, recov-
ery rate, and time to recovery. To avoid confounding fac-
tors, only the first event of skin toxicity was analyzed. For 
rash management interventions, standard Japanese ranking 
of steroids was used, defining steroids as strongest (e.g., 
clobetasol propionate), very strong (e.g., dexamethasone 
propionate), strong (e.g., betamethasone valerate), medium 
(e.g., hydrocortisone butyrate), and weak (e.g., hydrocor-
tisone acetate) [16]. Patients were categorized into sub-
groups according to the topical steroid treatment they 
received (weak- or medium-rank steroids categorized as 
‘medium,’ strong, or higher-rank steroids categorized as 
‘strong,’ and those initiated on medium-rank or lower ster-
oids then changed to strong-rank or higher-rank steroids 
were categorized as ‘medium to strong’). Time to recovery 
was estimated from Kaplan–Meier curves.
Results
Patients
A total of 10,708 patients were enrolled between December 
2007 and October 2009 from 1027 institutions; of these, 
9,909 patients were evaluated for this analysis. Baseline 
characteristics are shown in Table 1. Briefly, the median 
patient age was 66 years; the majority of patients (80.2 %) 
had adenocarcinoma histology; 44 % of patients had an 
ECOG PS of 1; and 29.7 % of patients had ECOG PS of 0.
Incidence of skin toxicity
The most common skin toxicities were acneiform rash, 
xeroderma, and paronychia, observed in 60.9 %, 7.5 %, and 
6.6 % of the study population, respectively. The majority of 
these skin toxicities were mild in severity, as grade 3/4 acnei-
form rash, xeroderma, and paronychia were reported in only 
6.3 %, 0.3 %, and 0.7 % of patients, respectively (Table 2). 
Three grade 5 skin toxicities reported: one case of toxic skin 
eruption and two cases of Stevens–Johnson syndrome.
The median time from erlotinib administration to onset 
of acneiform rash was within 2 weeks (9 days), xero-
derma was within 3 weeks (16 days), and paronychia was 
approximately 5 weeks (34 days) from initial erlotinib 
administration.
Interventions for skin toxicity
The most common intervention for the treatment of skin 
toxicities was topical steroids, with more than 75 % of 
patients who suffered from acneiform rash (the most com-
mon skin toxicity) receiving steroids within 4 days of diag-
nosis. Of the patients experiencing xeroderma, more than 
75 % received steroids within 5 days of onset or diagnosis, 
and many patients with paronychia were already on ster-
oids, for an average of 10 days, before diagnosis or onset of 
paronychia.
Regardless of rash grade, earlier initiation of topical 
steroids resulted in quicker recovery (Fig. 1). Although 
the early initiation groups (before onset, 0–1, 2–6, and 
7–13 days) had similar median recovery times (30–39 days 
depending on initiation group for grade 1 rash, 48–51 days 
depending on initiation group for grade 2 rash), there was 
a noticeable increase in recovery time from the 14–20 days 
Table 1  Baseline characteristics of the analysis population 
(N = 9909)
ECOG PS Eastern Cooperative Oncology Group performance status
N %
Gender
 Male 5300 53.5
 Female 4609 46.5
Age (years)
 Median (range) 66 (14–95) –
Histology
 Adenocarcinoma 7950 80.2
 Other 1935 19.5
 Unknown 24 0.24
Stage
 Relapsed 3316 33.5
 IIIB 1387 14.0
 IV 4917 49.6
 Other 202 2.0
 Unknown 87 0.9
ECOG PS
 0 2935 29.6
 1 4380 44.2
 2 1786 18.0
 3 604 6.1
 4 186 1.9
 Unknown 18 0.2
Table 2  Erlotinib-related skin 
toxicities by grade (N = 9909) N (%) Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total
Acneiform rash 2415 (24.4) 2944 (29.7) 598 (6.0) 23 (0.2) 1 (0.0) 6032 (60.9)
Xeroderma 422 (4.3) 286 (2.9) 24 (0.2) 1 (0.0) 0 738 (7.5)
Paronychia 274 (2.8) 303 (3.1) 70 (0.7) 0 0 654 (6.6)
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group (93 days for grade 1 rash, 71 days for grade 2 rash). 
In the group initiated more than 21 days after onset, recov-
ery appeared to be considerably longer than the other 
groups, resulting in a recovery time of more than 100 days 
regardless of rash grade, compared with the before onset 
groups who had median time to recovery of 35–51 days 
depending on rash grade.
Median time to recovery stratified by steroid strength 
and by grade of rash is shown in Fig. 2. Time to recovery 
in patients who were changed to strong- or higher-rank 
steroids (medium to strong) was longer than that observed 
in other groups. Median time to recovery of rash in the 
medium- to strong-rank steroids subgroup was 47, 98, and 
103 days for those with grade 1, 2, and 3 rash, respectively; 
this is compared with 39, 53, and 73 days median recov-
ery for grade 1, 2, and 3 rash, respectively, in patients in 
the strong-rank steroid subgroup. In patients who received 
medium-rank steroids for grade 1, 2, or 3 rash, 21.9 %, 
36.5 %, and 47.5 % of patients, respectively, needed to 
have their treatment changed to strong-rank steroids.
The trend of patients in the medium to strong subgroup 
having longer recovery time than those responding to 
medium-rank steroids or those initiated on strong-rank ster-
oids was also seen in patients who did not have erlotinib 
dose reduction or interruption (Supplementary Fig. 1).
In patients with grade 2 rash (the most common grade 
of rash), there was again a trend of patients in the medium 
to strong subgroup having longer recovery times than 
the other two groups, regardless of time of steroid initia-
tion (Supplementary Fig. 2). In patients with grade 2 rash, 
there was a trend of earlier initiation of steroid, resulting in 
shorter recovery time, regardless of steroid rank.
Discussion
This analysis focused on the incidence and management of 
rash in POLARSTAR, as skin toxicities are one of the most 
common AEs associated with erlotinib, with rash being the 
most common skin toxicity experienced. As rash can have 
an impact on patients’ quality of life and may lead to dis-
continuation of treatment, effective rash management is 
required to ensure patients remain on erlotinib for as much 
of the treatment course as possible to gain maximal ben-
efit. As erlotinib treatment is often given for an extended 
period of time, particularly in patients with EGFR muta-
tions, the development of effective rash management strate-
gies to ameliorate ongoing rash symptoms is vital, particu-
larly as prophylactic rash treatments have not yet been fully 
validated. Effective management strategies are especially Fig. 1  Time to recovery according to time to treatment initiation: 
grade 1 rash (a), grade 2 rash (b), grade ≥3 rash (c)
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important when considering that some data indicate a cor-
relation between increased rash grade and erlotinib effi-
cacy, meaning those with the most severe rash, who may 
wish to discontinue treatment, may actually be gaining the 
most benefit from erlotinib [11–14].
The majority of skin toxicities reported in the 
POLARSTAR Japanese surveillance study were grade 
1/2. Acneiform rash was the most common skin toxic-
ity observed, seen in 60.9 % of patients. Earlier initia-
tion of topical steroid treatment for erlotinib-related rash 
resulted in reduced recovery time. Patients who were initi-
ated on strong-rank steroids had a shorter recovery time 
than patients who failed to respond to medium-rank steroids 
and then progressed to strong-rank steroids, regardless of 
whether patients received additional erlotinib dose reduc-
tion or interruption for rash. These data suggest that earlier 
initiation of treatment (within 0–14 days of diagnosis) with 
strong-ranked or higher-rank steroids could be a suitable 
administration regimen for rash management in erlotinib-
treated NSCLC patients. Patients who were initiated on 
medium-rank steroids had the shortest recovery time; how-
ever, some patients needed to change steroid rank (21.9 % 
of patients with grade 1 rash, 36.5 % with grade 2 rash, and 
47.5 % with grade 3 rash needed to change from medium- or 
weaker-rank steroids to stronger-rank steroids). Furthermore, 
patients who needed to change steroid rank had the longest 
recovery time. This finding suggests there may be some risk 
of undertreatment with medium-rank steroids because it is 
difficult to determine precisely whether medium-rank ster-
oids have enough intensity for each case before treatment 
initiation. Additionally, undertreatment with medium-rank 
steroids could lead to longer recovery time than initiation 
with strong-rank steroids. Therefore, if there is no adequate 
reason for avoiding administration of strong-rank steroids 
(e.g., concomitant skin infection), it might be more effective 
to initiate all patients on strong- or higher-rank steroids for 
maximal benefit and quicker recovery time.
There are various ways to manage erlotinib-related rash. 
A recent review by Kiyohara et al. highlighted very strong/
strong class steroids as a recommended treatment for EGFR-
related acneiform rash [15]. In addition to steroids rang-
ing from hydrocortisone to methylprednisolone for varying 
grades of rash, patient education is also seen as important for 
prophylactic treatment (teaching patients about moisturiza-
tion, reducing sun exposure, and avoiding products that dry 
the skin) [6]. Novel treatments, such as menadione lotion, 
retinoids, and alpha-hydroxy acids, are also being inves-
tigated as possible treatment options for erlotinib-related 
rash [6]. Earlier steroid treatments for skin toxicities and 
even pre-emptive regimens have been effective in reducing 
EGFR TKI-related rash. Lacouture et al. showed that pre-
emptive steroid treatment reduced the incidence of grade ≥2 
skin toxicities by 50 % compared with reactive treatment in 
Fig. 2  Class effects of steroids for rash management: grade 1 rash 
(a), grade 2 rash (b), and grade ≥3 rash (c). Medium: patients treated 
with medium- or weak-rank steroids; medium to strong: patients ini-
tially treated with medium- or weak-rank steroids then changed to 
strong- or higher-rank steroids; strong: patients treated with strong- or 
higher-rank steroids
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colorectal cancer patients treated with panitumumab [29 % 
vs. 62 % of patients: odds ratio 0.3; 95 % confidence interval 
(CI), 0.1–0.6] [17]. However, these novel pre-emptive treat-
ments are neither fully established nor validated; therefore, 
adequate reactive steroid treatment is still a key management 
strategy in the current scenario.
To our knowledge, this is the first analysis focusing 
on the correlation between steroid rank, timing of ini-
tiation of steroid treatment, and recovery time of rash 
induced by erlotinib. However, there are a number of 
factors to consider when interpreting data from this anal-
ysis. As this was a single-arm surveillance study, there 
was no control group with which to directly compare 
results. The study design meant that in contrast to a clin-
ical trial, there was no strict observation period, and the 
study lacked any patient selection criteria, as all patients 
treated with erlotinib in Japan in the post-approval 
period were enrolled.
Conclusion
As most current treatment algorithms are based on anec-
dotal evidence, and this study provides evidence to support 
the use of topical steroids for EGFR TKI-associated rash, 
further studies should be undertaken to corroborate our 
findings that strong topical steroids initiated early in skin 
toxicity diagnosis are a suitable regimen to treat these AEs 
to allow continuation of EGFR TKI therapy.
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